US-based medical device company Strata Skin Sciences has received Japan’s Ministry of Health, Labor and Welfare (MHLW) approval for its XTRAC Momentum 1.0 device.
XTRAC Momentum is the next-generation excimer laser system that facilitates the precise delivery of targeted UVB light to treat specific areas on the skin.
The excimer laser can be used for both adult and paediatric patients suffering from inflammatory skin conditions such as psoriasis, atopic dermatitis, and vitiligo.
The medical device company plans to commercially launch the device in Japan through JMEC, its established strategic partner and distributor in Japan.
Strata president and CEO Dolev Rafaeli said: “With this regulatory approval, we are now able to offer the Momentum device, our most advanced excimer laser, into the Japanese dermatology market.
“Working with JMEC, we look forward to introducing doctors and patients to the benefits of Momentum for the treatment of various dermatology conditions, such as psoriasis, eczema, and vitiligo.”
Strata Skin Sciences is a medical technology company focused on developing, commercialising, and marketing innovative products for treating dermatologic conditions.
The medical device maker initially launched the XTRAC Momentum in the US in 2022.
Strata said its new XTRAC Momentum is the latest addition to its excimer laser technology and delivers higher power and a rapid repetition rate than the current models.
XTRAC Momentum also provides a new user interface and slim design to improve the treatment experience.
Furthermore, the medical technology company said that its excimer devices are now used by more than 300 hospitals and private practice dermatology clinics in Japan.
